Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
Malecki
Maciej T
MT
Department of Metabolic Diseases, Jagiellonian University, Medical College, 15 Kopernika St., 31-501 Krakow, Poland. mmalecki@cm-uj.krakow.pl
Skupien
Jan
J
Klupa
Tomasz
T
Wanic
Krzysztof
K
Mlynarski
Wojciech
W
Gach
Agnieszka
A
Solecka
Iwona
I
Sieradzki
Jacek
J
D000328:Adult; D017668:Age of Onset; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D005786:Gene Expression Regulation; D006580:Genetic Carrier Screening; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000235:genetics*; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D008297:Male; D009154:Mutation; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D000099161:Kcnj11 Channel
D007004:Hypoglycemic Agents; D007328:Insulin; D024661:Potassium Channels, Inwardly Rectifying; D013453:Sulfonylurea Compounds; D000099161:Kcnj11 Channel